NCT06635850 (PHocus) is a Phase 2 clinical trial of Mosliciguat in Pulmonary Hypertension, sponsored by Pulmovant, Inc..

Who is sponsoring NCT06635850?

NCT06635850 is sponsored by Pulmovant, Inc..

What drugs are being tested in NCT06635850?

Interventions in NCT06635850: Mosliciguat, Dry Powder Inhaler, Placebo.

What condition does NCT06635850 study?

NCT06635850 studies Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis.

Is NCT06635850 still recruiting?

NCT06635850 is currently active, enrolled. Last updated 19 February 2026.

Last reviewed 2026-02-19 · How we verify

NCT06635850: PHocus

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

Active, enrolled Phase 2 Last updated 19 February 2026

What this trial tests

Phase 2 trial testing Mosliciguat in Pulmonary Hypertension in 135 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

29 October 2024

Primary endpoint
1 December 2026

1 January 2028

Quick facts

Lead sponsor	Pulmovant, Inc.
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	135
Start date	29 October 2024
Primary completion	1 December 2026
Estimated completion	1 January 2028
Sites	18 locations across United States

Drugs / interventions tested

Mosliciguat — full drug profile →
Dry Powder Inhaler
Placebo

Conditions studied

Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
Interstitial Lung Disease — all drugs for Interstitial Lung Disease →
Lung Diseases — all drugs for Lung Diseases →
Vascular Diseases — all drugs for Vascular Diseases →

Sponsor

Pulmovant, Inc. — full company profile →

Who can join

Adults 18 to 85, any sex, with Pulmonary Hypertension or Interstitial Lung Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)
Time frame: Baseline, Week 16
PVR evaluated using right heart catheterization (RHC).

Sponsor's own description

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
Kattih Z, Kim HC, Aryal S, Nathan SD. · · 2025 · cited 2× · PMID 40142837 · DOI 10.3390/jcm14062029
Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men.
Saleh S, Mundry T, Nagelschmitz J, Buetehorn U, et al · · 2025 · cited 1× · PMID 40402373 · DOI 10.1007/s40262-025-01503-6
Abstracts From PVRI 2026 Dublin
· 2026

Verify or expand the search:

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06635850 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pulmovant, Inc.
Last refreshed: 19 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06635850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing